Market Snapshot
S&P Futures
4,132.5
Dow Futures
32,787
Nasdaq Futures
13,107.75
Annexon, Inc. (ANNX) stock rallied over 0.19% intraday to trade at $5.23 a share on NASDAQ. The stock opened with a gain of 4.81% at $5.24 and touched an intraday high of $5.33, rising 0.19% against the last close of $5.22. The stock went to a low of $5.1 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-08-08 | $5.24 | $5.33 | $5.1 | $5.23 | 163,942 |
2022-08-05 | $4.99 | $5.255 | $4.97 | $5.22 | 226,300 |
2022-08-04 | $5.05 | $5.11 | $4.91 | $5.03 | 98,200 |
2022-08-03 | $4.78 | $5.19 | $4.78 | $4.91 | 181,600 |
2022-08-02 | $4.52 | $4.738 | $4.52 | $4.69 | 78,900 |
2022-08-01 | $5.01 | $5.01 | $4.45 | $4.52 | 304,100 |
2022-07-29 | $5.21 | $5.21 | $4.88 | $5.01 | 175,800 |
2022-07-28 | $5.22 | $5.37 | $5.16 | $5.27 | 129,700 |
2022-07-27 | $5.15 | $5.22 | $4.95 | $5.19 | 141,200 |
2022-07-26 | $4.93 | $5.13 | $4.86 | $5.1 | 196,300 |
1400 Sierra Point Parkway
Building C Suite 200
Brisbane, CA 94005
United States
Webiste:ANNX
Employees-
Beta-
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barre syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Annexon, Inc. (NASDAQ: ANNX) stock price is $5.23 as of the last check on Monday, August 8. During the trading session, ANNX stock reached the peak price of $5.33 while $5.1 was the lowest point it dropped to.
The NASDAQ listed ANNX is part of Biotechnology industry that operates in the broader Health Care sector. Annexon, Inc. , a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders.
Dr. Sanjay Keswani B.Sc., MBBS
Exec. VP & Chief Medical Officer
Mr. Douglas Love J.D., Esq.
CEO, Pres & Director
Dr. Larry C. Mattheakis Ph.D.
Exec. VP & Chief Scientific Officer
Dr. Ted Yednock Ph.D.
Exec. VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board
ANNX stock traded closed the last session at $5.23, which is $0.010000000000000675 or 0.19157088122606658% lower than its previous close of $5.22. ANNX's current trading price is 153.88% lower than its 52-week high of $23.61 where as its distance from 52-week low of 2.06% is -77.85%.
Number of ANNX employees currently stands at -. ANNX operates from 1400 Sierra Point Parkway, Building C Suite 200, Brisbane, CA 94005, United States.
Official Webiste of $ANNX is: https://www.annexonbio.com
ANNX could be contacted at ANNX operates from 1400 Sierra Point Parkway, Building C Suite 200, Brisbane, CA 94005, United States, or at phone #650 822 5500 and can also be accessed through its website.
ANNX stock volume for the day was 164,198 shares while in the previous session number of ANNX shares traded was 163,942 . The average number of ANNX shares traded daily for last 3 months was 452.82 Thousands.
The percentage change in ANNX stock occurred in the recent session was 0.19157088122606658% while the dollar amount for the price change in ANNX stock was $0.010000000000000675.
In the recent session, the day high for ANNX stock was $5.33 while the low for ANNX stock touched on the day was $5.1.
The market value of ANNX currently stands at 194.35 Million with its latest stock price at $5.23 and 38.56 Million of its shares outstanding.